Expression of telomerase reverse transcriptase positively correlates with duration of lithium treatment in bipolar disorder.
Adult
Aging
/ genetics
Antimanic Agents
/ therapeutic use
Bipolar Disorder
/ blood
Cellular Senescence
/ drug effects
Female
Humans
Lithium
/ therapeutic use
Lithium Compounds
/ pharmacology
Male
Middle Aged
Mitochondria
/ metabolism
Oxidative Stress
/ drug effects
Polymorphism, Single Nucleotide
/ genetics
Real-Time Polymerase Chain Reaction
Telomerase
/ drug effects
Telomere
/ drug effects
Telomere Homeostasis
/ genetics
Telomere Shortening
/ drug effects
Affective disorder
Aging
Mitochondria
Oxidative stress
TERT
Telomere
Journal
Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
07
12
2019
revised:
07
02
2020
accepted:
11
02
2020
pubmed:
3
3
2020
medline:
18
9
2020
entrez:
2
3
2020
Statut:
ppublish
Résumé
Bipolar disorder (BD) may be associated with accelerated cellular aging. However, previous studies on telomere length (TL), an important biomarker of cellular aging, have yielded mixed results in BD. We aimed to evaluate the hypothesis that BD is associated with telomere shortening and whether this is counteracted by long-term lithium treatment. We also sought to determine whether long-term lithium treatment is associated with increased expression of telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase. We determined TL and TERT expression in 100 BD I patients and 100 healthy controls. We also genotyped three single nucleotide polymorphisms associated with TL. TERT expression was significantly increased in BD I patients currently on lithium treatment. TERT expression was also significantly positively correlated with duration of lithium treatment in patients treated for 24 months or more. However, we did not find any significant effect of lithium treatment on TL. Neither did we find significant differences in TL between BD patients and controls. We suggest that long-term lithium treatment is associated with an increase in the expression of TERT. We hypothesize that an increase in TERT expression may contribute to lithium's mood stabilizing and neuroprotective properties by improving mitochondrial function and decreasing oxidative stress.
Identifiants
pubmed: 32114208
pii: S0165-1781(19)32437-0
doi: 10.1016/j.psychres.2020.112865
pmc: PMC7334059
mid: NIHMS1572757
pii:
doi:
Substances chimiques
Antimanic Agents
0
Lithium Compounds
0
Lithium
9FN79X2M3F
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
112865Subventions
Organisme : NCI NIH HHS
ID : R01 CA204013
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet. 2013 May 11;381(9878):1672-82
pubmed: 23663953
Cells. 2019 Jan 19;8(1):
pubmed: 30669451
J Biol Chem. 2012 Sep 21;287(39):32494-511
pubmed: 22854964
Bipolar Disord. 2013 Dec;15(8):832-8
pubmed: 24021055
Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):822-9
pubmed: 22199369
Drug Discov Today. 2015 Nov;20(11):1305-9
pubmed: 26166813
Eur Neuropsychopharmacol. 2014 Jul;24(7):1139-43
pubmed: 24731723
Psychiatry Res. 2011 Jun 30;188(1):129-32
pubmed: 21300409
Neurosci Biobehav Rev. 2014 May;42:157-69
pubmed: 24548785
Neurosci Biobehav Rev. 2017 Mar;74(Pt A):1-20
pubmed: 28093238
J Affect Disord. 2011 Dec;135(1-3):43-50
pubmed: 21880373
J Natl Cancer Inst. 2015 Apr 10;107(6):djv074
pubmed: 25862531
Curr Pharm Des. 2014;20(41):6386-403
pubmed: 24975608
Braz J Psychiatry. 2018 Jan-Mar;40(1):19-25
pubmed: 28700015
J Neurosci. 2015 Jan 28;35(4):1659-74
pubmed: 25632141
J Exp Med. 1999 Jul 19;190(2):157-67
pubmed: 10432279
Eur Neuropsychopharmacol. 2016 Jul;26(7):1241-7
pubmed: 27084304
Psychiatry Clin Neurosci. 2017 Feb;71(2):77-103
pubmed: 27800654
Biol Psychiatry. 2006 Sep 1;60(5):432-5
pubmed: 16581033
Nucleic Acids Res. 2009 Feb;37(3):e21
pubmed: 19129229
Mayo Clin Proc. 2013 Sep;88(9):952-62
pubmed: 24001487
Int J Bipolar Disord. 2015 Dec;3(1):30
pubmed: 26105627
Antioxidants (Basel). 2017 Feb 28;6(1):
pubmed: 28264499
Transl Psychiatry. 2013 May 21;3:e261
pubmed: 23695236
Lancet. 2016 Apr 9;387(10027):1561-1572
pubmed: 26388529
Curr Alzheimer Res. 2016;13(8):853-61
pubmed: 26892287
Int J Neuropsychopharmacol. 2015 Jan 24;18(7):pyv002
pubmed: 25618407
Front Neurosci. 2015 Oct 27;9:403
pubmed: 26578864
Philos Trans R Soc Lond B Biol Sci. 2018 Mar 5;373(1741):
pubmed: 29335378
CNS Drugs. 2016 Oct;30(10):931-49
pubmed: 27638546
Nucleic Acids Res. 2014 Jul;42(13):8565-77
pubmed: 24990373
Curr Psychiatry Rep. 2012 Dec;14(6):667-75
pubmed: 23090632
Front Cell Dev Biol. 2019 Nov 06;7:274
pubmed: 31781563
Hum Genet. 2015 Jul;134(7):679-89
pubmed: 25986438
Science. 2015 Dec 4;350(6265):1193-8
pubmed: 26785477
Genes (Basel). 2016 Jun 16;7(6):
pubmed: 27322326
Acta Psychiatr Scand. 2014 Nov;130(5):354-63
pubmed: 24961757
J Neurochem. 2017 Nov;143(4):418-431
pubmed: 28397282
J Affect Disord. 2015 Feb 1;172:43-7
pubmed: 25451394
Eur Neuropsychopharmacol. 2017 Jun;27(6):560-567
pubmed: 26621262
FEBS Lett. 2015 Apr 13;589(9):974-84
pubmed: 25749370